JP2023554692A - 線維筋痛症のためのシクロベンザプリン処置 - Google Patents

線維筋痛症のためのシクロベンザプリン処置 Download PDF

Info

Publication number
JP2023554692A
JP2023554692A JP2023542924A JP2023542924A JP2023554692A JP 2023554692 A JP2023554692 A JP 2023554692A JP 2023542924 A JP2023542924 A JP 2023542924A JP 2023542924 A JP2023542924 A JP 2023542924A JP 2023554692 A JP2023554692 A JP 2023554692A
Authority
JP
Japan
Prior art keywords
mannitol
cyclobenzaprine hcl
eutectic
composition
cyclobenzaprine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554692A5 (https=
Inventor
セス レーダーマン，
グレゴリー エム． サリバン，
Original Assignee
トニックス ファーマシューティカルズ ホールディング コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トニックス ファーマシューティカルズ ホールディング コーポレイション filed Critical トニックス ファーマシューティカルズ ホールディング コーポレイション
Publication of JP2023554692A publication Critical patent/JP2023554692A/ja
Publication of JP2023554692A5 publication Critical patent/JP2023554692A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023542924A 2020-12-07 2021-12-07 線維筋痛症のためのシクロベンザプリン処置 Pending JP2023554692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122469P 2020-12-07 2020-12-07
US63/122,469 2020-12-07
PCT/US2021/062244 WO2022125572A1 (en) 2020-12-07 2021-12-07 Cyclobenzaprine treatment for fibromyalgia

Publications (2)

Publication Number Publication Date
JP2023554692A true JP2023554692A (ja) 2023-12-28
JP2023554692A5 JP2023554692A5 (https=) 2024-12-17

Family

ID=79686930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542924A Pending JP2023554692A (ja) 2020-12-07 2021-12-07 線維筋痛症のためのシクロベンザプリン処置

Country Status (9)

Country Link
US (2) US20240024256A1 (https=)
EP (1) EP4255407A1 (https=)
JP (1) JP2023554692A (https=)
CN (1) CN116940340A (https=)
AU (1) AU2021396509A1 (https=)
CA (1) CA3204202A1 (https=)
IL (1) IL303497A (https=)
MX (1) MX2023006720A (https=)
WO (1) WO2022125572A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3260042A1 (en) * 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF A (SARS)-COV-2 (PASC) INFECTION
WO2025137348A1 (en) * 2023-12-19 2025-06-26 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532374A (ja) * 2014-09-18 2017-11-02 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
WO2020039256A1 (en) * 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63822B1 (sr) 2012-06-15 2023-01-31 Tonix Pharma Holdings Ltd Kompozicije i postupci za transmukoznu apsorpciju
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532374A (ja) * 2014-09-18 2017-11-02 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
WO2020039256A1 (en) * 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS AND REUMATOLOGY, vol. Vol.71, Suppl.10, Abstract No.837, JPN6025041231, 2019, ISSN: 0005700891 *

Also Published As

Publication number Publication date
AU2021396509A1 (en) 2023-06-29
WO2022125572A1 (en) 2022-06-16
CN116940340A (zh) 2023-10-24
EP4255407A1 (en) 2023-10-11
US20240024256A1 (en) 2024-01-25
CA3204202A1 (en) 2022-06-16
MX2023006720A (es) 2023-08-18
IL303497A (en) 2023-08-01
US20260108477A1 (en) 2026-04-23
AU2021396509A9 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US20260108477A1 (en) Cyclobenzaprine treatment for fibromyalgia
CN101772346B (zh) 用于降低治疗副作用的方法和组合物
JP2002539245A5 (https=)
Esparza-Villalpando et al. Comparison of the analgesic efficacy of preoperative/postoperative oral dexketoprofen trometamol in third molar surgery: A randomized clinical trial
AU2014372739B2 (en) Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
TW201417807A (zh) 於一個體中改善甲狀腺功能之方法
TW202019400A (zh) 治療急性壓力症候群及創傷後壓力症候群之方法
Mystakidou et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics
Bellino et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study
JPWO2013089164A1 (ja) 高度腎機能障害を有する血栓塞栓症患者の血栓塞栓症の予防治療剤
JP2023554692A5 (https=)
HK40102591A (zh) 纤维肌痛的环苯紮林治疗
JP2006508118A5 (https=)
US20250322926A1 (en) Early onset response, favorable tolerability, and side effect profile in the treatment of fibromyalgia
EP3976012A1 (en) Intranasal administration of ketamine to cluster headache patients
Ozkan et al. The evaluation of safety and analgesic efficacy of paracetamol and ibuprofen followed by impacted third molar surgery
Eslamian et al. Does Benzocaine Toothpaste Have More Pain-Relieving Effect Compared To Placebo Toothpaste In Orthodontic Patients? A Double-Blind Randomized Controlled Trial
Woroń Drug selection in the treatment of breakthrough pain: how the pharmacokinetic profile of drugsis to be translated into clinical practice
US11826326B2 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
Al-juma Comparison of the Onset of Diclofenac Potassium Sachet (Voltfast) and EntericCoated Diclofenac Potassium (Cataflam) in Treatment of Pain Following Tooth Extraction
CA2959004A1 (en) Composition for improving cognitive function
Sikdar et al. Dapoxetine for the management of premature ejaculation
DING et al. Compound of vitamin D and Calcium or combining with bisphosphonates in preventing bone loss induced by glucocorticoid
Bali et al. Comparison of Pretreatment by Different Analgesics on Post-operative Endodontic Pain: A Clinical Study
Mystakidou et al. Pain and symptom management. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403